市场概况

The Immunoglobulins Market is projected to reach USD 24.29 十亿 2029, with a 6.3% CAGR 2023 到 2029. Immunoglobulins are glycoprotein molecules produced by plasma cells in response to antigens. The pandemic has impacted the plasma derivatives industry, increasing costs despite lower volumes collected. 然而, advancements in immunoglobulin products for rare and autoimmune diseases have fueled market growth. Technological developments in plasma fractionation and partnerships with plasma collection agencies are driving the market.

该报告涵盖了市场规模和增长, 分割, 竞争格局, trends and strategies for global immunoglobulins market. 它提供了对市场的定量分析，使利益相关者能够利用当前的市场机会. 该报告还根据市场趋势和主要竞争对手的方法确定了最重要的机会和战略细分市场.

市场细分

市场根据多种因素进行细分, 包括产品, 应用, 最终用户, 和地理.
产品: intramuscular immunoglobulin (IMIg), intravenous immunoglobulin (IVIg), subcutaneous immunoglobulin (SCIg)
应用: primary immunodeficiency, chronic immune deficiency polyradiculoneuropathy, secondary immunodeficiency, 免疫血小板细胞减少性紫癜, 肌无力重症, 其他的
最终用户: 医院和诊所, 家庭护理

按地理位置细分
北美 – 美国, 加拿大
欧洲 - 德国, 法国, 英国, 意大利, 西班牙
亚太地区 – 中国, 日本, 印度, 韩国, 澳大利亚
拉丁美洲 – 巴西, 墨西哥, 阿根廷
中东 & 非洲 – 南非, 沙特阿拉伯, 火鸡

IVIg is commonly used in the management of autoimmune diseases and immunodeficiency. It involves administering immunoglobulins intravenously for maximum bioavailability and efficacy. Primary immunodeficiency is the leading segment, 占 26.3% of the global immunoglobulins market in 2022. Symptoms of primary immunodeficiencies include recurring infections, 炎, and low platelet count. Hospitals and clinics are the largest end-users in the market, but home care is expected to grow rapidly due to the rising demand for home healthcare services.

North America accounted for 46.4% of the global immunoglobulins market in 2022, supported by factors such as increased personal health awareness, patient-centric healthcare, advanced infrastructure, a robust plasma collection network, and prominent global vendors. Europe is the second-largest market, driven by high demand and a well-regulated market with a focus on safe blood and plasma collection. The Asia-Pacific (亚太地区) region is an emerging market, particularly for autoimmune disorder treatments. China leads the APAC market due to its population’s high awareness of blood donation and its importance in manufacturing life-saving products.

竞争格局

The industry is dominated by CSL Limited, 武田制药有限公司, and Grifols S.A. These vendors face intense competition and strive to gain an advantage through new product introductions and regulatory approvals. Emerging markets and low-resource countries offer opportunities for new entrants due to larger populations and willingness to donate blood or plasma. Plasma procurement is crucial for vendors, leading to the establishment of extensive collection networks. Partnerships with official plasma collection agencies have driven growth for many vendors. Key companies profiled include ADMA Biologics Inc., Bharat Serums And Vaccines Limited (BSV), Biotest AG, China Biologic Products, 公司. (Shandong Taibang Biological Products Co., 有限公司), CSL Limited, Grifols, S.A., 约翰逊 & 约翰逊, Kedrion Biopharma Inc. (Kedrion SpA), LFB S.A., Octapharma AG, Reliance Life Sciences Pvt. 有限公司, Shanghai RAAS Blood Products Co., 有限公司, 武田制药有限公司, and Zydus Lifesciences Limited.

报告范围

To analyze and forecast the market size of the global immunoglobulins market.
To classify and forecast the global immunoglobulins market based on product, 应用, 最终用户, 地理.
To identify drivers and challenges for the global immunoglobulins market.
检查合并等竞争性发展 & 收购, 协议, 合作与伙伴关系, ETC。, in the global immunoglobulins market.
To identify and analyze the profile of leading players operating in the global immunoglobulins market.

为什么选择这份报告

Gain a reliable outlook of the global immunoglobulins market forecasts from 2023 到 2029 跨场景.
确定投资的增长领域.
通过公司简介和市场数据领先于竞争对手.
Excel 格式的跨场景分析易用性的市场预估.
三个月的战略咨询和研究支持.
为单用户许可证提供打印验证.